sr 33557 has been researched along with moxifloxacin in 1 studies
Studies (sr 33557) | Trials (sr 33557) | Recent Studies (post-2010) (sr 33557) | Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) |
---|---|---|---|---|---|
50 | 3 | 1 | 3,157 | 552 | 1,690 |
Protein | Taxonomy | sr 33557 (IC50) | moxifloxacin (IC50) |
---|---|---|---|
DNA gyrase subunit B | Staphylococcus aureus | 5.1033 | |
DNA gyrase subunit A | Escherichia coli K-12 | 1.4 | |
DNA gyrase subunit B | Escherichia coli K-12 | 1.4 | |
DNA topoisomerase 4 subunit A | Staphylococcus aureus | 0.8 | |
DNA gyrase subunit A | Staphylococcus aureus | 7.25 | |
DNA gyrase subunit B | Mycobacterium tuberculosis H37Rv | 8.525 | |
DNA gyrase subunit A | Mycobacterium tuberculosis H37Rv | 8.66 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B | 1 |
1 other study(ies) available for sr 33557 and moxifloxacin
Article | Year |
---|---|
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers | 2012 |